|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Bioxel Pharma (BIP.V): Grant of Options and Deferred Stock Units
4/11/2008 9:19:46 AM
SAINTE-FOY, QUEBEC--(Marketwire - April 10, 2008) - Bioxel Pharma Inc.(TSX VENTURE: BIP), a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, today announced that, on March 27, 2008, its Board of Directors granted 365,000 common share purchase options to its officers and employees, pursuant to its stock option plan. These options were granted at an exercise price of $0.135 per share, being the closing price of the Corporation's common shares on the TSX Venture Exchange on the last business day preceding the grant date. It should be pointed out that 769,000 options expired between January 1 and April 8, 2008.
|
|
|
|
|
|
|
|
|
|
|